Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 18/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623823 | 0.83 | GRM5 (0.45) | GRM5 | |
| SCHEMBL18623827 | 0.83 | GRM5 (0.34) | GRM5 | |
| SCHEMBL17080356 | 0.83 | GRM5 (0.34) | GRM5TGFBR1 | |
| SCHEMBL18623822 | 0.82 | GRM5 (0.43) | GRM5 | |
| SCHEMBL18623831 | 0.81 | GRM5 (0.34) | GRM5 | |
| SCHEMBL18623820 | 0.80 | DYRK1A (0.40) | DYRK1AGRM5 | |
| SCHEMBL18623828 | 0.80 | GRM5 (0.32) | GRM5 | |
| SCHEMBL18623803 | 0.80 | GRM5 (0.32) | GRM5 | |
| SCHEMBL17080366 | 0.78 | ABL1 (0.34) | GRM5TGFBR1 | |
| SCHEMBL18623805 | 0.78 | GABRA1 (0.34) | GRM5TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C3AR1 | DYRK1A 563/4885GRM5 1798/4885TGFBR1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.